Beta-Lactamase Resistance and Inhibitors

Beta-lactamases are bacterial enzymes that hydrolyse the beta-lactam ring before it can reach its target, and they are the most important mechanism of resistance to this antibiotic class. Beta-lactamase inhibitors are companion molecules that bind and disable these enzymes, restoring the activity of a partner beta-lactam.

Definition

Beta-lactamases are enzymes that catalyse hydrolysis of the beta-lactam ring, inactivating the antibiotic; beta-lactamase inhibitors are compounds that bind these enzymes (covalently or non-covalently) to protect a co-administered beta-lactam.

Scope

This topic covers the mechanism and classification of beta-lactamases, the spread of extended-spectrum and carbapenem-hydrolysing enzymes, the chemistry and rationale of beta-lactamase inhibitors, and the role of mobile genetic elements in disseminating resistance. It is a reference overview and offers no prescribing guidance.

Core questions

• How do beta-lactamases inactivate beta-lactam antibiotics?
• How are beta-lactamases classified, and what are ESBLs and carbapenemases?
• How do beta-lactamase inhibitors restore activity, and why are they paired with a beta-lactam?

Key concepts

• Beta-lactam ring hydrolysis
• Ambler molecular classes (A, B, C, D)
• Serine beta-lactamases vs metallo-beta-lactamases
• Extended-spectrum beta-lactamases (ESBLs)
• Carbapenemases
• Beta-lactamase inhibitors
• Suicide (mechanism-based) inhibition
• Mobile genetic elements and gene transfer

Mechanisms

Most beta-lactamases are serine hydrolases that, like penicillin-binding proteins, form an acyl-enzyme with the beta-lactam — but they then hydrolyse it rapidly, regenerating active enzyme and destroying the drug; metallo-beta-lactamases instead use zinc ions to hydrolyse the ring (Bush & Bradford, 2016). The enzymes are grouped by the Ambler molecular classification into serine classes A, C and D and the metallo class B, a scheme that organizes their substrate range and inhibitor susceptibility. Extended-spectrum beta-lactamases broaden hydrolysis to many cephalosporins, and carbapenemases extend it to carbapenems (Fisher & Mobashery, 2016). Classical beta-lactamase inhibitors such as clavulanic acid act as mechanism-based ('suicide') inhibitors that covalently trap susceptible serine enzymes, while newer diazabicyclooctane and boronate inhibitors cover additional enzyme classes; because inhibitors generally lack useful antibacterial activity themselves, they are co-formulated with a partner beta-lactam (Drawz & Bonomo, 2010). The wide distribution of these enzymes reflects carriage of their genes on plasmids, transposons and integrons that move between bacteria (Partridge et al., 2018).

Clinical relevance

Beta-lactamases explain much of the loss of beta-lactam activity over time, and inhibitor combinations are a central strategy for preserving these drugs; the topic is foundational for teaching antimicrobial resistance and stewardship. This entry describes mechanisms and drug classes for educational orientation and is not a basis for dosing or treatment decisions.

Epidemiology

Beta-lactamase-mediated resistance is a global problem: extended-spectrum beta-lactamases are widespread in Enterobacterales, and carbapenemases (serine enzymes such as KPC and metallo-enzymes such as NDM) have disseminated internationally. Their spread is propelled by mobile genetic elements that transfer resistance genes within and across species (Partridge et al., 2018; Bush & Bradford, 2016).

Evidence & guidelines

Detection and reporting of beta-lactamases rest on standardized phenotypic and molecular testing and on breakpoints from bodies such as EUCAST and CLSI, while resistance surveillance informs stewardship frameworks; this overview summarizes the underlying enzymology and inhibitor strategy rather than any specific guideline.

History

The phenomenon predates penicillin's wide use: Abraham and Chain (1940) reported a bacterial enzyme able to destroy penicillin, the first description of what became known as beta-lactamase. Successive waves of enzymes — staphylococcal penicillinase, plasmid-mediated broad-spectrum enzymes, extended-spectrum beta-lactamases and carbapenemases — followed each new beta-lactam, and beta-lactamase inhibitors were developed from the 1970s onward to counter them (Drawz & Bonomo, 2010; Bush & Bradford, 2016).

Key figures

• Edward Abraham
• Ernst Chain
• Karen Bush
• Robert Bonomo

Seminal works

• abraham-chain-1940
• drawz-bonomo-2010
• bush-bradford-2016

Frequently asked questions

What does a beta-lactamase do?

It is a bacterial enzyme that hydrolyses (breaks open) the beta-lactam ring of the antibiotic, inactivating the drug before it can disable the cell-wall transpeptidase target.

Why are beta-lactamase inhibitors given together with a beta-lactam?

Most inhibitors have little antibacterial activity of their own; they bind and disable the beta-lactamase so that the partner beta-lactam can reach its target, which is why they are co-formulated rather than used alone.